Jump to Main Content

Advocacy

Policy Statements

The American Society of Hematology represents the interests of hematologists and their patients before Congress and the Executive branch, advocating for the best science and practice of hematology. When warranted, ASH issues policy statements on research, practice, training, or quality of care issues that are likely to have an impact on the field.

Submit
Reset

Access to Hematology Care in an Age of Innovation

Nov 22
2019

The American Society of Hematology (ASH) believes that all individuals should have access to and be able to afford high-quality, clinically appropriate care, including innovative therapeutics. Hematologists treat patients with malignant hematologic d...

Read more

ASH Statement in Support of Palliative Blood Transfusions in Hospice Setting

Jun 25
2019

The American Society of Hematology (ASH) represents approximately 17,000 physicians, scientists, and medical trainees committed to the study and treatment of blood and blood-related diseases. As an organization of physicians and scientists who care f...

Read more

Statement on Opioid Use in Patients with Hematologic Diseases and Disorders

Apr 18
2018

The American Society of Hematology (ASH) represents approximately 17,000 physicians, scientists, and medical trainees committed to the study of blood and treatment of blood-related diseases. ASH members include clinicians who specialize in treating c...

Read more

ASH Policy Statement in Support of Patient Access to Safe and Effective Drugs

Jan 06
2017

ASH Policy Statement in Support of Patient Access to Safe and Effective DrugsAs an organization of physicians and scientists who care for desperately ill patients, including those with blood cancers such as leukemia, lymphoma, and myeloma, as well as...

Read more

Statement on Screening for Sickle Cell Trait and Athletic Participation

Jan 26
2012

Background The American Society of Hematology (ASH) represents approximately 16,000 physicians, scientists, and medical trainees committed to the study and treatment of blood and blood-related diseases. ASH members include clinicians who specialize i...

Read more

Frequently Asked Questions Regarding Sickle Cell Trait

Jan 25
2012

Sickle cell trait is an inherited blood disorder affects approximately 8 percent of African-Americans. Unlike sickle cell disease, a serious illness in which patients have two genes that cause the production of abnormal hemoglobin, ind...

Read more

Statement in Support of All Avenues of Stem Cell Research

Oct 18
2010

As an organization of physicians who care for desperately ill patients and scientists devoted to understanding the basic mechanisms of disease and discovering new therapies, the American Society of Hematology (ASH) is excited about the scientific pot...

Read more

Statement on Clinical Research and Trials

Sep 16
2010

Clinical research in hematology has never been more important, yet clinical hematology investigators are facing unprecedented challenges. Constantly changing and often inconsistent regulations, chaotic reimbursement policies, lack of insurance covera...

Read more

Statement on Regenerative Medicine

Apr 15
2010

American Society of Hematology (ASH) represents over 16,000 clinicians and scientists committed to the study and treatment of blood and blood-related diseases. Hematologists were instrumental in characterizing the first stem cell identified in the bl...

Read more

Principles for Health Care Reform

Dec 01
2009

Guarantee by law that everyone has access to affordable health care, from prevention, to treatment, to end-of-life care Eliminate health care discrepancies between race, ethnicity, sex, age, income, education, urban, rural, and other so...

Read more